Study of ME-401 in subjects with relapsed or refractory indolent B-cell non-Hodgkin's lymphoma (NHL)
- Conditions
- Indolent B-cell Non-Hodgkin's Lymphoma (NHL)
- Registration Number
- JPRN-jRCT2080225353
- Lead Sponsor
- Kyowa Kirin Co., Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 60
Patients with relapsed or refractory B-cell NHL who is categorized into SLL, WM, LPL by WHO classification
- Patients who have been histologically confirmed FL Grade 3b transformation from FL to an aggressive lymphoma at least once
- Patients with lymphomatous involvement of the central nervous system
- Patients with uncontrolled clinically significant illness
- Patients with active interstitial lung disease or a history thereof
- Patients with relapsed or refractory B-cell NHL who is categorized into SLL, WM, LPL by WHO classification
- Patients who have been histologically confirmed FL Grade 3b transformation from FL to an aggressive lymphoma at least once
- Patients with lymphomatous involvement of the central nervous system
- Patients with uncontrolled clinically significant illness
- Patients with active interstitial lung disease or a history thereof
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method